Avacta Group plc (AIM: AVCT) shares opened lower today following the announcement of a successful, yet discounted, placing and subscription that raised £10 million. The funds were secured through the issue of 15,000,000 new Ordinary Shares via a placing and 873,016 new Ordinary Shares via subscription, both priced at 63 pence per share.
The Issue Price represents a 9.35 percent discount to the closing mid-market price of 69.5 pence on March 25, 2026, the last trading day before the announcement. This discount likely contributed to the initial downward pressure on the share price as markets digested the news.
Directors Richard Hughes and David Bryant participated in the subscription, investing £500,000 and £50,000 respectively. Hughes now holds 0.17 percent of the enlarged share capital, while Bryant holds 0.02 percent. Their participation is viewed as a related party transaction, but has been deemed fair and reasonable by the independent directors after consulting with Strand Hanson, the company’s Nominated Adviser.
Zeus Capital, acting as sole broker and bookrunner, also subscribed for 317,476 Ordinary Shares at the Issue Price, amounting to £0.2 million. This too, constitutes a related party transaction due to Richard Hughes’ association with Zeus Capital.
As part of the agreement with Zeus Capital, Avacta will issue warrants over 4,364,457 Ordinary Shares, representing 0.96 percent of the company’s enlarged share capital. These warrants are exercisable at 63 pence per share for a period of five years, expiring on April 7, 2031. Zeus Capital has agreed not to dispose of any shares issued through the warrants before April 7, 2027, and then only in consultation with Avacta.
Admission of the new shares to trading on AIM is expected to occur on or around April 7, 2026. Following Admission, Avacta’s enlarged issued ordinary share capital will be 456,288,511 Ordinary Shares. This figure is important for shareholders calculating their notification requirements under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
Analyst Summary: Bull and Bear Cases
Bull Case:
- Funding Boost: The £10 million raised strengthens Avacta’s balance sheet and provides capital to advance its pre|CISION® oncology platform.
- Director Confidence: Insider participation in the subscription signals confidence in the company’s prospects, despite the discounted price.
- Zeus Capital Incentive: The issuance of warrants incentivizes Zeus Capital to support Avacta’s share price performance over the long term.
Bear Case:
- Short-term Selling Pressure: The discounted placing, while providing necessary capital, has likely triggered short-term selling pressure. The market will now focus on how Avacta deploys the funds to progress its clinical programs and generate shareholder value.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading or investing in financial markets. Dive in and test their capabilities with complimentary demo accounts today!
- IG Top-tier regulation – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
